Abstract: A method, system, and article is directed to automatic content-dependent image processing algorithm selection.

Abstract: An ionic compound, an absorbent and an absorption device are provided. The ionic compound has a structure represented by Formula (I): ABn, ??Formula (I) wherein A is B is R1, R2, R3, R4, R5, and R6 are independently H, C1-6 alkyl group; and n is 1 or 2.

Abstract: A packaging substrate assembly for fabricating a packaged module can include a packaging substrate having a surface, and an array of conductive pads implemented on the surface. The assembly can further include a conductive post formed over each conductive pad, with the conductive post including a first portion having a lateral dimension formed over the conductive pad and a second portion having a lateral dimension formed over the first portion. In some embodiments, the lateral dimension of the first portion is less than the lateral dimension of the second portion. In some embodiments, a dielectric layer can be implemented over the surface to cover the conductive pads and surround the first portion of each conductive post.

Abstract: A semiconductor device comprises a first semiconductor structure, a second semiconductor structure located on the first semiconductor structure, and an active layer located between the first semiconductor structure and the second semiconductor structure. The first semiconductor structure has a first conductivity type, and includes a plurality of first layers and a plurality of second layers alternately stacked. The second semiconductor structure has a second conductivity type opposite to the first conductivity type. The plurality of first layers and the plurality of second layers include indium and phosphorus, and the plurality of first layers and the plurality of second layers respectively have a first indium atomic percentage and a second indium atomic percentage. The second indium atomic percentage is different from the first indium atomic percentage.

Abstract: The present invention relates generally to a method of generating cells exhibiting multilineage potential and to cells generated thereby. More particularly, the present invention is directed to an in vitro method of generating mammalian stem cells from CD4* mononuclear cells, CD8* mononuclear cells, CD25* mononuclear cells, CD19* mononuclear cells or CD20* mononuclear cells and to cells generated thereby. This finding has now facilitated the design of means for reliably and efficiently generating populations of multilineage potential cells, such as stem cells, for use in a wide variety of clinical and research settings. These uses include, inter alia, the directed differentiation, either in vitro or in vivo, of the subject multilineage potential cells and the therapeutic or prophylactic treatment of a range of conditions either via the administration of the multilineage potential cells of the invention or the more fully differentiated cellular populations derived therefrom.

Abstract: The present invention relates to a method of treating a neoplastic condition in a mammal. More particularly, the present invention is directed to a method of treating solid tumours, such as primary tumours, secondary tumours, and metastatic tumours. The method of the present invention is predicated on down-regulating the growth of neoplastic cells by administering stem cells or a population of multilineage progenitor cells (MLPC) which have been generated in vitro.

Abstract: The present invention relates generally to a method of generating cells exhibiting multilineage potential and to cells generated thereby. More particularly, the present invention is directed to an in vitro method of generating mammalian stem cells from CD14+ mononuclear cells and to cells generated thereby. This finding has now facilitated the design of means for reliably and efficiently generating populations of multilineage potential cells, such as stem cells,for use in a wide variety of clinical and research settings. These uses include, inter alia, the directed differentiation, either in vitro or in vivo, of the subject multilineage potential cells and the therapeutic or prophylactic treatment of a range of conditions either via the administration of the multilineage potential cells of the invention or the more fully differentiated cellular populations derived therefrom.

Abstract: Active fragments of hcrmp1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer and methods of using the same for treating cancer are disclosed. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. Vectors capable of expressing an hcrmp1, variants of hcrmp1, fragments of hcrmp1 and/or variants of fragments of hcrmp1 are also disclosed.

Abstract: The present invention discloses a method for treating cancer by using hCRMP1 and/or active fragments thereof, as well as the active fragments of hCRMP1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. A vector capable of expressing an hCRMP1, a variant of hCRMP1, a fragment of hCRMP1 or a variant of a fragment of hCRMP1 is also disclosed.

Abstract: This invention provides a transcription unit which is isolated from the upstream nucleic acid sequence of the collapsing response mediator protein-1 (CRMP-1) gene, an invasion-suppressor gene. The transcription unit contains a nucleic acid regulatory sequence which demonstrates promoter and/or regulatory activities (such as providing a transcription factor binding site) to enhance the expression of the CRMP-1 and/or a reporter protein. The invention also provides a DNA construct containing this transcription unit which can be transfected into a host cell. Additionally, the invention provides methods to enhance the expression of CRMP-1 and/or the reporter protein. The over-expression of CRMP-1 in a cancer cell can inhibit the metastasis of the cancer cell.

Abstract: The present invention discloses a method for treating cancer by using hCRMP1 and/or active fragments thereof, as well as the active fragments of hCRMP1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. A vector capable of expressing an hCRMP1, a variant of hCRMP1, a fragment of hCRMP1 or a variant of a fragment of hCRMP1 is also disclosed.

Abstract: This invention provides a transcription unit which is isolated from the upstream nucleic acid sequence of the collapsing response mediator protein-1 (CRMP-1) gene, an invasion-suppressor gene. The transcription unit contains a nucleic acid regulatory sequence which demonstrates promoter and/or regulatory activities (such as providing a transcription factor binding site) to enhance the expression of the CRMP-1 and/or a reporter protein. The invention also provides a DNA construct containing this transcription unit which can be transfected into a host cell. Additionally, the invention provides methods to enhance the expression of CRMP-1 and/or the reporter protein. The over-expression of CRMP-1 in a cancer cell can inhibit the metastasis of the cancer cell.

Abstract: This invention provides a transcription unit which is isolated from the upstream nucleic acid sequence of the collapsing response mediator protein-1 (CRMP-1) gene, an invasion-suppressor gene. The transcription unit contains a nucleic acid regulatory sequence which demonstrates promoter and/or regulatory activities (such as providing a transcription factor binding site) to enhance the expression of the CRMP-1 and/or a reporter protein. The invention also provides a DNA construct containing this transcription unit which can be transfected into a host cell. Additionally, the invention provides methods to enhance the expression of CRMP-1 and/or the reporter protein. The over-expression of CRMP-1 in a cancer cell can inhibit the metastasis of the cancer cell.